Abstract
Alzheimer’s disease (AD) is one of the most common types of dementia whose hallmarks include neurofibrillary tangles and senile plaques. The latter are mainly composed of amyloid-β proteins (Aβ), and it’s suggested that Aβ may be the causative factor in AD pathogenesis. Immunotherapy targeting Aβ for preventing aggregation of Aβ and mildly clearing amyloid plaques has been a hot topic since 1999. Although the first clinical trial of Aβ vaccine, AN-1792, failed in phase II, its results suggested some key points in the design of Aβ vaccines. Avoiding the possible toxic Aβ specific T cell response and inducing a Th2 type cellular immune response may be beneficial for Aβ immunotherapy. Many associations and research groups are working on Aβ vaccine and some progress has been made in recent years. In this review, we have provided a detailed summary of past Aβ vaccines, which have been sorted by the immunogen, and we also discuss some recent progress and future perspectives.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Wimo A, Prince M. Alzheimer’s Disease International. World Alzheimer Report 2010, 2010
Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A. Immunotherapy for Alzheimer’s disease: from anti-beta-amyloid to tau-based immunization strategies. Immunotherapy, 2012, 4: 213–238
Hamley IW. The amyloid beta peptide: a chemist’s perspective. Role in Alzheimer’s and fibrillization. Chem Rev, 2012, 112: 5147–5192
Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science, 1992, 256: 184–185
Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med, 2008, 14: 837–842
Schenk D, Basi GS, Pangalos MN. Treatment strategies targeting amyloid beta-protein. CSH Perspect Med, 2012, 2: a006387
Wu WH, Lei P, Liu Q, Hu J, Gunn AP, Chen MS, Rui YF, Su XY, Xie ZP, Zhao YF, Bush AI, Li YM. Sequestration of copper from beta-amyloid promotes selective lysis by cyclen-hybrid cleavage agents. J Biol Chem, 2008, 283: 31657–31664
Panza F, Logroscino G, Imbimbo BP, Solfrizzi V. Is there still any hope for amyloid-based immunotherapy for Alzheimer’s disease? Curr Opin Psychiatr, 2014, 27: 128–137
Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 1999, 400: 173–177
Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology, 2003, 61: 46–54
Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med, 2003, 9: 448–452
Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer’s disease. Brain Pathol, 2004, 14: 11–20
Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, Van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M. Bapineuzumab 201 clinical trial I. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology, 2009, 73: 2061–2070
Monsonego A, Weiner HL. Immunotherapeutic approaches to Alzheimer’s disease. Science, 2003, 302: 834–838
Monsonego A, Maron R, Zota V, Selkoe DJ, Weiner HL. Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer’s disease. Proc Natl Acad Sci USA, 2001, 98: 10273–10278
Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, Babikyan D, Kesslak P, Kieber-Emmons T, Cotman CW, Agadjanyan MG. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol, 2003, 15: 505–514
Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, Budson AE, Sperling R, Selkoe DJ, Weiner HL. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest, 2003, 112: 415–422
Monsonego A, Imitola J, Petrovic S, Zota V, Nemirovsky A, Baron R, Fisher Y, Owens T, Weiner HL. Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA, 2006, 103: 5048–5053
Tabira T. Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. Tohoku J Exp Med, 2010, 220: 95–106
Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M, Saing T, Cribbs DH. Prototype Alzheimer’s disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol, 2005, 174: 1580–1586
Liu B, Frost JL, Sun J, Fu H, Grimes S, Blackburn P, Lemere CA. MER5101, a novel Abeta1-15:DT conjugate vaccine, generates a robust anti-Abeta antibody response and attenuates Abeta pathology and cognitive deficits in APPswe/PS1DeltaE9 transgenic mice. J Neurosci, 2013, 33: 7027–7037
Kou J, Song M, Pattanayak A, Lim J E, Yang J, Cao D, Li L, Fukuchi K. Combined treatment of Abeta immunization with statin in a mouse model of Alzheimer’s disease. J Neuroimmunol, 2012, 244: 70–83
Arai H, Suzuki H, Yoshiyama T, Lobello K, Peng Y, Liu E, Ketter N, Margolin R, Jackson N, Fujimoto Y. Safety, tolerability and immunogenicity of an immunotherapeutic vaccine (vanutide cridificar [ACC-001]) and the QS-21 adjuvant in Japanese individuals with mild-to-moderate Alzheimer’s disease: a phase IIa, multicenter, randomized, adjuvant and placebo clinical trial. Alzheimers Dement, 2013, 9: P282
Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol, 1997, 15: 617–648
Movsesyan N, Ghochikyan A, Mkrtichyan M, Petrushina I, Davtyan H, Olkhanud PB, Head E, Biragyn A, Cribbs DH, Agadjanyan MG. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine: a novel immunotherapeutic strategy. PLoS One, 2008, 3: e2124
Kim HD, Tahara K, Maxwell JA, Lalonde R, Fukuiwa T, Fujihashi K, Van Kampen KR, Kong FK, Tang DC, Fukuchi K. Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer’s disease. J Gene Med, 2007, 9: 88–98
Lewis PJ, Van Drunen Littel-Van Den H, Babiuk LA. Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response. J Virol, 1999, 73: 10214–10223
Boutajangout A, Goni F, Knudsen E, Schreiber F, Asuni A, Quartermain D, Frangione B, Chabalgoity A, Wisniewski T, Sigurdsson EM. Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine. J Alzheimers Dis, 2009, 18: 961–972
Wiessner C, Wiederhold KH, Tissot AC, Frey P, Danner S, Jacobson LH, Jennings GT, Luond R, Ortmann R, Reichwald J, Zurini M, Mir A, Bachmann MF, Staufenbiel M. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci, 2011, 31: 9323–9331
Ishii Y, Nakae T, Sakamoto F, Matsuo K, Matsuo K, Quan YS, Kamiyama F, Fujita T, Yamamoto A, Nakagawa S, Okada N. A transcutaneous vaccination system using a hydrogel patch for viral and bacterial infection. J Control Release, 2008, 131: 113–120
Matsuo K, Okamoto H, Kawai Y, Quan YS, Kamiyama F, Hirobe S, Okada N, Nakagawa S. Vaccine efficacy of transcutaneous immunization with amyloid beta using a dissolving microneedle array in a mouse model of Alzheimer’s disease. J Neuroimmunol, 2014, 266: 1–11
Wang S, Yu Y, Geng S, Wang D, Zhang L, Xie X, Wu B, Li C, Xu H, Li X, Hu Y, Zhang L, Kaether C, Wang B. A coimmunization vaccine of Abeta42 ameliorates cognitive deficits without brain inflammation in an Alzheimer’s disease model. Alzheimers Res Ther, 2014, 6: 26
Wang CM, Devries S, Camboni M, Glass M, Martin PT. Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer’s disease. Neurobiol Dis, 2010, 39: 409–422
Camboni M, Wang CM, Miranda C, Yoon JH, Xu R, Zygmunt D, Kaspar BK, Martin PT. Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APPswePSEN1dE9 mouse model for Alzheimer’s disease. Neurobiol Dis, 2014, 62: 31–43
Kang C. Identification of peptides that specifically bind Aβ1-40 amyloid in vitro and amyloid plaques in Alzheimer’s disease brain using phage display. Neurobiol Dis, 2003, 14: 146–156
Schneeberger A, Mandler M, Otawa O, Zauner W, Mattner F, Schmidt W. Development of AFFITOPE vaccines for Alzheimer’s disease (AD): from concept to clinical testing. J Nutr Health Aging, 2009, 13: 264–267
Acero G, Manoutcharian K, Vasilevko V, Munguia ME, Govezensky T, Coronas G, Luz-Madrigal A, Cribbs DH, Gevorkian G. Immunodominant epitope and properties of pyroglutamate-modified Abeta-specific antibodies produced in rabbits. J Neuroimmunol, 2009, 213: 39–46
Perez-Garmendia R, Ibarra-Bracamontes V, Vasilevko V, Luna-Munoz J, Mena R, Govezensky T, Acero G, Manoutcharian K, Cribbs DH, Gevorkian G. Anti-11[E]-pyroglutamate-modified amyloid beta antibodies cross-react with other pathological Abeta species: relevance for immunotherapy. J Neuroimmunol, 2010, 229: 248–255
Dalgediene I, Lasickiene R, Budvytyte R, Valincius G, Morkuniene R, Borutaite V, Zvirbliene A. Immunogenic properties of amyloid beta oligomers. J Biomed Sci, 2013, 20: 10
Rasool S, Albay R 3rd, Martinez-Coria H, Breydo L, Wu J, Milton S, Misra S, Tran A, Pensalfini A, Laferla F, Kayed R, Glabe CG. Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice. Mol Neurodegener, 2012, 7: 37
Webster SJ, Mruthinti S, Hill WD, Buccafusco JJ, Terry AV Jr. An aqueous orally active vaccine targeted against a RAGE/AB complex as a novel therapeutic for Alzheimer’s disease. Neuromol Med, 2012, 14: 119–130
Kofler J, Lopresti B, Janssen C, Trichel AM, Masliah E, Finn OJ, Salter RD, Murdoch GH, Mathis CA, Wiley CA. Preventive immunization of aged and juvenile non-human primates to beta-amyloid. J Neuroinflamm, 2012, 9: 84
Guan X, Zou J, Gu H, Yao Z. Short amyloid-beta immunogens with spacer-enhanced immunogenicity without junctional epitopes for Alzheimer’s disease immunotherapy. Neuroreport, 2012, 23: 879–884
Xing X, Sha S, Li Y, Zong L, Jiang T, Cao Y. Immunization with a new DNA vaccine for Alzheimer’s disease elicited Th2 immune response in BALB/c mice by in vivo electroporation. J Neurol Sci, 2012, 313: 17–21
Sha S, Xing XN, Guo WS, Li Y, Zong LX, Guo R, Cao YP. In vivo electroporation of a new gene vaccine encoding ten repeats of Abeta3–10 prevents brain Abeta deposition and delays cognitive impairment in young Tg-APPswe/PSEN1dE9 mice. Neurochem Res, 2012, 37: 1534–1544
Li Y, Ma Y, Zong LX, Xing XN, Guo R, Jiang TZ, Sha S, Liu L, Cao YP. Intranasal inoculation with an adenovirus vaccine encoding ten repeats of Abeta3-10 reduces AD-like pathology and cognitive impairment in Tg-APPswe/PSEN1dE9 mice. J Neuroimmunol, 2012, 249: 16–26
Olkhanud PB, Mughal M, Ayukawa K, Malchinkhuu E, Bodogai M, Feldman N, Rothman S, Lee JH, Chigurupati S, Okun E, Nagashima K, Mattson MP, Biragyn A. DNA immunization with HBsAg-based particles expressing a B cell epitope of amyloid beta-peptide attenuates disease progression and prolongs survival in a mouse model of Alzheimer’s disease. Vaccine, 2012, 30: 1650–1658
Tan L, Wang H, Tan X, Zou J, Yao Z. Yeast expressed foldable quadrivalent Abeta15 elicited strong immune response against Abeta without Abeta-specific T cell response in wild C57BL/6 mice. Hum Vacc Immunother, 2012, 8: 1090–1098
Davtyan H, Ghochikyan A, Petrushina I, Hovakimyan A, Davtyan A, Poghosyan A, Marleau AM, Movsesyan N, Kiyatkin A, Rasool S, Larsen AK, Madsen PJ, Wegener KM, Ditlevsen DK, Cribbs DH, Pedersen LO, Agadjanyan MG. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer’s disease: prelude to a clinical trial. J Neurosci, 2013, 33: 4923–4934
Feng G, Wang W, Qian Y, Jin H. Anti-Abeta antibodies induced by Abeta-HBc virus-like particles prevent Abeta aggregation and protect PC12 cells against toxicity of Abeta1-40. J Neurosci Meth, 2013, 218: 48–54
Guan X, Yang J, Gu H, Zou J, Yao Z. Immunotherapeutic efficiency of a tetravalent Abeta1-15 vaccine in APP/PS1 transgenic mice as mouse model for Alzheimer’s disease. Hum Vacc Immunother, 2013, 9: 1643–1653
Guo W, Sha S, Xing X, Jiang T, Cao Y. Reduction of cerebral Abeta burden and improvement in cognitive function in Tg-APPswe/PSEN1 dE9 mice following vaccination with a multivalent Abeta3-10 DNA vaccine. Neurosci Lett, 2013, 549: 109–115
Matsumoto Y, Niimi N, Kohyama K. Development of a new DNA vaccine for Alzheimer disease targeting a wide range of abeta species and amyloidogenic peptides. PLoS One, 2013, 8: e75203
Richter M, Hoffmann R, Singer D. T-cell epitope-dependent immune response in inbred (C57BL/6J, SJL/J, and C3H/HeN) and transgenic P301S and Tg2576 mice. J Pept Sci, 2013, 19: 441–451
Yano A, Miwa Y, Kanazawa Y, Ito K, Makino M, Imai S, Hanada N, Nisizawa T. A novel method for enhancement of peptide vaccination utilizing T-cell epitopes from conventional vaccines. Vaccine, 2013, 31: 1510–1515
Yu YZ, Wang S, Bai JY, Zhao M, Chen A, Wang WB, Chang Q, Liu S, Qiu WY, Pang XB, Xu Q, Sun ZW. Effective DNA epitope chimeric vaccines for Alzheimer’s disease using a toxin-derived carrier protein as a molecular adjuvant. Clin Immunol, 2013, 149: 11–24
Yu YZ, Wang WB, Chen A, Chang Q, Liu S, Zhao M, Wang S, Qiu WY, Pang XB, Xu Q, Sun ZW. Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer’s disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Abeta1-15 fused to toxin-derived carrier proteins. J Alzheimers Dis, 2014, 41: 243–260
Mantile F, Trovato M, Santoni A, Barba P, Ottonello S, De Berardinis P, Prisco A. Alum and squalene-oil-in-water emulsion enhance the titer and avidity of anti-A beta antibodies induced by multimeric protein antigen (1–11)E2, preserving the Igg1-skewed isotype distribution. Plos One, 2014, 9
Davtyan H, Ghochikyan A, Hovakimyan A, Davtyan A, Cadagan R, Marleau AM, Albrecht RA, Garcia-Sastre A, Agadjanyan MG. A dual vaccine against influenza & Alzheimer’s disease failed to enhance anti-beta-amyloid antibody responses in mice with pre-existing virus specific memory. J Neuroimmunol, 2014, 277: 77–84
Li S, Wei Z, Chen J, Chen Y, Lv Z, Yu W, Meng Q, Jin Y. Oral administration of a fusion protein between the cholera toxin b subunit and the 42-amino acid isoform of amyloid-beta peptide produced in silkworm pupae protects against Alzheimer’s disease in mice. PLoS One, 2014, 9: e113585
Mastelic B, Ahmed S, Egan WM, Del Giudice G, Golding H, Gust I, Neels P, Reed SG, Sheets RL, Siegrist CA, Lambert PH. Mode of action of adjuvants: implications for vaccine safety and design. Biologicals, 2010, 38: 594–601
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, G., Chen, YX. & Li, YM. New progress in active immunotherapy targeting to amyloid beta. Sci. China Chem. 58, 383–389 (2015). https://doi.org/10.1007/s11426-014-5310-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11426-014-5310-9